Q4 2025 · 13F-HR
Commodore Capital LPholdings as filed
Filed 2026-02-17 · accession 0001831942-26-000004
$1.50B
Reported value
33
Positions
2025-12-31
Period end
The Brief · Commodore Capital LP · Q4 2025
AI · grounded in 13F
Commodore Capital LP closed its position in MERUS N V, reducing its exposure by $331.8M. The fund also exited positions in AGIO for $93.8M and VRDN for $69M. To offset these sales, the fund established new positions in ANRO for $32.4M and PALI for $26.8M. Additionally, the fund increased its holdings in AMLX and SYRE by 38.6% and 20.1% respectively.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 75943R102 | RLAY | RELAY THERAPEUTICS INC | $143.8M | 9.57% | 17,000,000 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $99.3M | 6.61% | 3,550,000 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $88.7M | 5.91% | 3,375,000 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $80.7M | 5.37% | 1,800,000 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $78.2M | 5.21% | 2,388,245 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $78.0M | 5.19% | 2,196,845 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $72.3M | 4.81% | 4,692,809 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $69.7M | 4.64% | 2,565,000 | Common | SOLE |
| 03237H101 | AMLX | AMYLYX PHARMACEUTICALS INC | $68.3M | 4.54% | 5,650,000 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $59.6M | 3.97% | 1,475,000 | Common | SOLE |
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $58.4M | 3.88% | 750,000 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $55.6M | 3.70% | 1,200,000 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $55.3M | 3.68% | 550,000 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $53.1M | 3.54% | 1,753,054 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $52.4M | 3.49% | 1,889,445 | Common | SOLE |
| 67080M103 | NRIX | NURIX THERAPEUTICS INC | $43.2M | 2.87% | 2,275,000 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $39.3M | 2.62% | 450,000 | Common | SOLE |
| 045396207 | ASMB | ASSEMBLY BIOSCIENCES INC | $34.0M | 2.26% | 1,000,000 | Common | SOLE |
| 50180M108 | LBRX | LB PHARMACEUTICALS INC | $33.4M | 2.22% | 1,500,000 | Common | SOLE |
| 23284F105 | CTMX | CYTOMX THERAPEUTICS INC | $32.8M | 2.18% | 7,692,300 | Common | SOLE |
| 02157Q109 | ANRO | ALTO NEUROSCIENCE INC | $32.5M | 2.16% | 1,823,196 | Common | SOLE |
| 696389402 | PALI | PALISADE BIO INC | $26.9M | 1.79% | 11,445,000 | Common | SOLE |
| 60255C885 | BRD1EUR | MIND MEDICINE MINDMED INC | $26.8M | 1.78% | 2,000,000 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $25.0M | 1.66% | 1,000,000 | Common | SOLE |
| 713317105 | PEPG | PEPGEN INC | $22.1M | 1.47% | 3,400,000 | Common | SOLE |
| 78397T202 | SABS | SAB BIOTHERAPEUTICS INC | $16.5M | 1.10% | 4,401,500 | Common | SOLE |
| 76029N106 | REPL | REPLIMUNE GROUP INC | $13.9M | 0.92% | 1,425,000 | Common | SOLE |
| 45719W205 | IKT | INHIBIKASE THERAPEUTICS INC | $11.1M | 0.74% | 5,397,488 | Common | SOLE |
| 21217B100 | CTNM | CONTINEUM THERAPEUTICS INC | $9.3M | 0.62% | 816,326 | Common | SOLE |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $8.8M | 0.58% | 483,000 | Common | SOLE |
| 75382E208 | RAPT | RAPT THERAPEUTICS INC | $8.5M | 0.56% | 250,000 | Common | SOLE |
| 04746L203 | LONA | ATHIRA PHARMA INC | $3.5M | 0.23% | 464,398 | Common | SOLE |
| 10919W405 | DRUG | BRIGHT MINDS BIOSCIENCES INC | $1.5M | 0.10% | 18,851 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.